Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

Per Soelberg Sorensen, Christian Ross, Katja Maria Clemmesen, Klaus Bendtzen, Jette Lautrup Frederiksen, Kai Jensen, Ole Kristensen, Thor Petersen, Soren Rasmussen, Mads Ravnborg, Egon Stenager, Nils Koch-Henriksen, Danish Multiple Sclerosis Study Group

348 Citationer (Scopus)

Abstract

Interferon beta is the first-line treatment for relapsing-remitting multiple sclerosis, but the drug can induce neutralising antibodies against itself, which might reduce effectiveness. We aimed to assess the clinical effect of neutralising antibodies.
OriginalsprogEngelsk
TidsskriftLancet
Vol/bind362
Udgave nummer9391
Sider (fra-til)1184-91
Antal sider8
ISSN0140-6736
DOI
StatusUdgivet - 11 okt. 2003

Fingeraftryk

Dyk ned i forskningsemnerne om 'Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis'. Sammen danner de et unikt fingeraftryk.

Citationsformater